FindMyKOL
Clinical trialNCT00073073CompletedPhase 2Interventional

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

NCT00073073 is a phase 2 interventional trial sponsored by Georgetown University. As of 21 Nov 2026, it is completed. It studies Exemestane in Breast Neoplasms. The registry lists an enrollment of 46 participants at 2 sites in 1 country. The registry lists a start date of 30 Nov 2003 and a primary completion date of 31 Dec 2011.

SponsorGeorgetown University →Enrollment46Breast Neoplasms
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00073073
FieldValue
Registry IDNCT00073073
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorGeorgetown University
Enrollment46
Registered sites2
Countries1
ConditionsBreast Neoplasms
DrugsExemestane
Start30 Nov 2003
Primary completion31 Dec 2011
Study completion31 Dec 2011
Last update posted17 May 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary goal of this 5-year study is to determine whether exemestane alone or in combination with celecoxib decreases breast tissue density in healthy postmenopausal women at high risk for breast cancer. Dense breast tissue seen on mammography has been linked to an increased risk of breast cancer. The study will also examine the effects of exemestane and celecoxib on bone density, blood hormone levels and quality of life. Exemestane, approved by the Food and Drug Administration for treating postmenopausal women with breast cancer, lowers the amount of estrogen in the body. Celecoxib, approved for treating arthritis pain and for reducing the number or colon polyps in an inherited syndrome, is an anti-inflammatory drug. Half of the women in the study will receive exemestane alone and half will receive exemestane and celecoxib together. In December 2004, the arm using exemestane and celecoxib was closed to accrual Postmenopausal women who are at increased risk for developing invasive breast cancer may be eligible to participate. Candidates are screened with breast cancer risk assessment, medical history and physical examination, blood tests, review of medical records, if needed, breast biopsy, and dual energy x-ray absorptiometry (DEXA) scan to assess bone density. For the DEXA scan, the subject lies still on a table for about 30 minutes while the spine and hip are scanned using a small amount of radiation. Participants take exemestane in pill form once a day for 2 years. They also take calcium and vitamin D pills daily to help protect bone health. They are followed in the clinic during the course of the study to determine the amount of drug taken and any side effects, and for the following tests and procedures: * Medical evaluation and blood tests at after 1 and 3 months on study drugs * Medical evaluation at 6 months * Breast biopsy at screening and then at 12 months * dual-emission x-ray absorptiometry (DEXA) scan of the spine, mammogram and routine blood tests before starting study drugs and then yearly for 5 years.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Suparna B Wedam, M.D.

    National Cancer Institute, National Institutes of Health

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

District of Columbia, United States1 site
  • Lombardi Cancer Center, Georgetown University

    Washington D.C.

Maryland, United States1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of Columbia: 1 siteDC1
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00073073

Each answer restates registry values shown on this page.

What is NCT00073073?

NCT00073073 is a phase 2 interventional trial sponsored by Georgetown University. It studies Exemestane in Breast Neoplasms.

Who leads NCT00073073?

The registry names Suparna B Wedam, M.D. (principal investigator, National Cancer Institute, National Institutes of Health) as the overall official.

Where does NCT00073073 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00073073 study?

The registered drug and biological interventions are Exemestane.

When did NCT00073073 end?

The registry lists a primary completion date of 31 Dec 2011 and a study completion date of 31 Dec 2011. The sponsor last updated the record on 17 May 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.